[18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer

Journal of Experimental & Clinical Cancer Research

Yasuyuki Suzuki¹  Tsutomu Masaki²  Hirohito Mori²  Reiko Kameyama⁴  Yuka Yamamoto⁴  Kunihiko Izuishi³  Ryusuke Takebayashi¹ 

[1] Department of Gastroenterological Surgery, Kagawa University 1750-1, Ikenobe, Miki, Kita, Kagawa 761-0793, Japan;Department of Internal Medicine of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University 1750-1, Ikenobe, Miki, Kita, Kagawa 761-0793, Japan;Department of Gastroenterological Surgery, Federation of Public Services and Affiliated Personnel Aid Associations, Takamatsu Hospital, 4-18 Tenjinmae, Takamatsu, Kagawa 760-0018, Japan;Department of Radiology, Kagawa University 1750-1, Ikenobe, Miki, Kita, Kagawa 761-0793, Japan

关键词: Hypoxia-inducible factor 1α;    Glucose transporter-1;    Gastric cancer;    Positron emission tomography;    18-Fluorodeoxyglucose;   

Others  :  825009
DOI  :  10.1186/1756-9966-32-34

 received in 2013-02-14, accepted in 2013-05-22,  发布年份 2013

【 摘 要 】

Background

The use of [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detection of gastric cancer is often debated because FDG uptake varies for each patient. The purpose of this study was to clarify the molecular mechanisms involved in FDG uptake.

Material and methods

Fifty patients with gastric cancer who underwent FDG-PET and gastrectomy were studied. Snap-frozen tumor specimens were collected and examined by real-time PCR for relationships between maximum standardized uptake value (SUV) and mRNA expression of the following genes: glucose transporter 1 (GLUT1), hexokinase 2 (HK2), hypoxia-inducible factor 1α (HIF1α), and proliferating cell nuclear antigen (PCNA).

Results

Tumor size was the only clinicopathological parameter that significantly correlated with SUV. Transcripts for the genes evaluated were about three-fold higher in malignant specimens than in normal mucosa, although only HIF1α was significantly correlated with SUV. When divided into intestinal and non-intestinal tumors, there was a significant correlation between SUV and tumor size in intestinal tumors. Interestingly, the weak association between SUV and HIF1α expression in intestinal tumors was substantially stronger in non-intestinal tumors. No correlation was found between SUV and mRNA expression of other genes in intestinal or non-intestinal tumors.

Conclusion

SUV was correlated with HIF1α, but not PCNA, HK2, or GLUT1 expression. FDG accumulation could therefore represent tissue hypoxia rather than glucose transport activity for aggressive cancer growth.

【 授权许可】

   
2013 Takebayashi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Shimada H, Okazumi S, Koyama M, Murakami K: Japanese gastric cancer association task force for research promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer 2011, 14:13-21.
• [2]Murakami K: FDG-PET for Hepatobiliary and pancreatic cancer: advances and current limitations. World J Clin Oncol 2011, 2:229-236.
• [3]Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D, Prenzel KL, Metzger R, Bollschweiler E, Hölscher AH, Mönig SP: Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010, 31:532-538.
• [4]Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH: Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005, 103:2383-2390.
• [5]Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K: Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004, 28:247-253.
• [6]Kamimura K, Nagamachi S, Wakamatsu H, Fujita S, Nishii R, Umemura Y, Ogita M, Komada N, Sakurai T, Inoue T, Fujimoto T, Nakajo M: Role of gastric distention with additional water in differentiating locally advanced gastric carcinomas from physiological uptake in the stomach on 18F-fluoro-2-deoxy-D-glucose PET. Nucl Med Commun 2009, 30:431-439.
• [7]Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006, 20:597-604.
• [8]Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001, 92:634-641.
• [9]Ott K, Herrmann K, Krause BJ, Lordick F: The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res 2008, 2:287-294.
• [10]Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ: Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008, 14:2012-2018.
• [11]Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003, 21:4604-4610.
• [12]Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, al-Kaisi N, Miraldi F: Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991, 32:1508-1512.
• [13]Avril N: GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004, 45:930-932.
• [14]Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
• [15]Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Higuchi T, Miyakubo M, Ishikita T, Nakajima T, Endo K: Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008, 22:83-86.
• [16]Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000, 32:792-797.
• [17]Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, Paudyal B, Iida Y, Hanaoka H, Ishikita T, Nakasone Y, Negishi A, Mogi K, Endo K: Diagnosis of maxillofacial tumor with L-3-[18F]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007, 21:129-135.
• [18]Baserga R: Growth regulation of the PCNA gene. J Cell Sci 1991, 98:433-436.
• [19]Hong SS, Lee H, Kim KW: HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004, 36:343-353.
• [20]Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Nishiyama Y, Mori H, Masaki T, Morishita A, Suzuki Y: Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D: -glucose positron emission tomography. J Gastrointest Surg 2012, 16:394-400.
• [21]Kameyama R, Yamamoto Y, Izuishi K, Sano T, Nishiyama Y: Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Nucl Med Commun 2011, 32:460-465.
• [22]Kuang Y, Schomisch SJ, Chandramouli V, Lee Z: Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol. 2006, 143:225-231.
• [23]Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, Mutri V, Funaioli C, Sperandi F, Giaquinta S, Martoni AA: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007, 10:221-227.
• [24]Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T: Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010, 15:588-593.
• [25]Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Masaki T, Suzuki Y: Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010, 14:1151-1158.
• [26]Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K, Sakuma T: Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg 2010, 58:405-410.
• [27]Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG: Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995, 60:1348-1352.
• [28]Ong LC, Jin Y, Song IC, Yu S, Zhang K, Chow PK: 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008, 49:1145-1153.
• [29]Dang CV, Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72.
• [30]Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
• [31]Berger KL, Nicholson SA, Dehdashti F, Siegel BA: FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000, 174:1005-1008.
• [32]Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009, 69:4918-4925.
• [33]Rajagopalan KN, DeBerardinis RJ: Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med 2011, 52:1005-1008.